BUSINESS
Aster DM Healthcare completes acquisition of Quality Care India through share swap
The transaction, valued at Rs 849 crore, involved no cash outflow for Aster DM Healthcare, and the merged entity will be jointly controlled by Aster promoters and BCP Asia.
BUSINESS
Healthify launches new weight loss program integrating GLP-1 therapy with lifestyle coaching
The program, developed with input from experts at Stanford, Harvard, and leading Indian endocrinologists, aims to maximize sustainable weight loss outcomes and minimize potential side effects associated with GLP-1 therapies.
BUSINESS
Caesarean procedures rise sharply, comprise 72.5% of deliveries in private hospitals: Study
Since caesarean surgeries are about 30 percent costlier than normal deliveries, they push up insurance premiums in the employers' group health insurance segment, a Prudent Insurance Broking study has said.
BUSINESS
BDR Pharma targeting 2027 for IPO launch, looking to acquire units in US, says CMD Dharmesh Shah
In the past few years, BDR Pharma has spent close to Rs 600 crore and plans to invest another Rs 700 crore to boost growth and acquisitions over the next three years
BUSINESS
Syngene expects slower growth in FY26 on inventory reset, expansion costs
Syngene reported a revenue growth of 4 percent at Rs 3,642 crore for FY25. Profit, however, was down 3%
BUSINESS
'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman
Some global companies have even proposed co-investments to set up manufacturing capacities, Vivek Sharma told Moneycontrol from the US.
BUSINESS
Laurus Labs bets on cell and gene therapies, eyes CDMO role
Laurus aims to leverage India's manufacturing prowess to serve global cell and gene therapy players targeting the Indian market, CEO Satyanarayana Chava has said
BUSINESS
AbbVie enters India oncology market with much-awaited launch of leukemia drug Venetoclax
The move comes as India grapples with a rising burden of AML, particularly among its aging population.
BUSINESS
Venus Remedies gets USFDA boost for potential antibiotic drug VRP-034
The QIDP status, granted by USFDA makes VRP-034 eligible for regulatory benefits including priority FDA review, potential fast-track designation, and an additional five years of market exclusivity in the U.S. upon approval.
BUSINESS
Zydus, Lupin seen weathering generic Myrbetriq court loss, says Elara report
An U.S. District Court recently ruled against Zydus and Lupin, finding Astellas's patent for Myrbetriq was not invalid. Both Indian drugmakers have been selling their generic versions of Myrbetriq "at risk" in the U.S. since the first quarter of fiscal year 2025.
BUSINESS
Cost and access drive international patients to India for CAR-T therapy
CAR-T therapy costs about Rs 50 lakh in India including hospital fees, much less than the Rs 3-4 crore or more (before hospital fees) in US, Germany, Spain, UK, Italy and France.
BUSINESS
Drug regulator to include outside experts in review panels for complex therapies
Central Drugs Standard Control Organisation (CDSCO) chief Rajeev Singh Raghuvanshi has described the move as a 'very important milestone' necessary to keep pace with innovation
BUSINESS
Indian medical device makers prepare for US push, sensing opportunity from China tariffs
Some of the India medical devices companies have started work on regulatory filings and paperwork, to ensure they do not miss out on the opportunity emerging out of this tariff war.
BUSINESS
Weight-loss drugs offer hope, but no magic pill for obesity, say experts
Such medications are just one part of a necessary, holistic approach that includes diet, exercise, and addressing significant societal stigma, say experts.
BUSINESS
Natco Pharma aims to launch generic of Roche’s rare disease drug after favourable ruling in patent infringement case
The company said it has decided to price its version of Risdiplam product at Rs 15,900, and further added that it intends to offer discount to certain deserving patients through its patient access programme.
BUSINESS
Lifestyle diseases striking younger in India warns Apollo Hospitals new report
The comprehensive study draws insights from de-identified electronic medical records encompassing over 2.5 million preventive health screenings conducted across Apollo’s vast ecosystem of hospitals, clinics, and diagnostic centres between 2019 and 2024.
BUSINESS
Trump tariffs to impact growth of Indian medical devices exports
According to Exports Promotion Council of Medical Devices, India's exports of medical devices to the US stood at $714.38 million, while imports from the US to India were significantly higher at $1.5 billion.
BUSINESS
Trump's move to exempt pharma from tariffs brings cheer to industry
The exemption applies broadly to all pharmaceutical products, ensuring that the drugmakers avoid immediate cost pressures
BUSINESS
Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle?
The Suven Life chairman is staking his fortune on a risky but potentially game-changing pipeline of central nervous system drugs, which are notoriously difficult to develop
BUSINESS
Gennova, CEPI ink pact to develop AI-enhanced Nipah vaccine with $13.4 million funding
At present, there is no approved vaccine or specific treatment exist for the virus, which has a mortality rate of 75 percent.
BUSINESS
FICCI caution members as US indict firms dealing in fentanyl precursors
The U.S. Department of Justice alleges that the companies facilitated the transportation, concealment, and sale of these substances within the US, in violation of federal law.
BUSINESS
Fentanyl: An explainer on the deadly opioid, Trump’s war and India's role
India with its vast pharmaceutical and chemical industries is an emerging source for fentanyl precursor chemicals. Mexican cartels purchase the precursors to make fentanyl which is shipped to the US.
BUSINESS
Delhi HC restrains Natco Pharma from launching generic of Roche's rare disease drug
"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche Pharma India spokesperson told Moneycontrol.
BUSINESS
Less than 1% of health claims in India are for mental health, report reveals
The finding was part of Marsh McLennan’s "RiseUP for a Better Tomorrow" Mental Health Report 2025
